PANMURE: Healthcare: Prescribed Reading : Sentiment improving…

PANMURE: Healthcare: Prescribed Reading : Sentiment improving…

PANMURE: Pharma Services : Stronger H2 still anticipated, but too early for upgrades

PANMURE: Oxford Biomedica : Vector with positive trajectory

PANMURE: Oxford Biomedica : Results in line, strong growth in KPI’s

PANMURE: Oxford Biomedica : Prelims preview: At the turning point?

PANMURE: Healthcare: Prescribed Reading : Mixed messages

PANMURE: Oxford Biomedica : New contracts underpin guidance

PANMURE: Oxford Biomedica : Guidance gives confidence in turnaround

PANMURE: Pharma Services : Headwinds easing; outlook points to a stronger H2

PANMURE: Healthcare: Prescribed Reading : The results preview edition

Hardman & Co Healthcare Index: 2023 – Capital demands dent performance

The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the second year running, apart from global economic influences affecting world markets, performance in 2023 was dented by the capital-intensive nature of the sector. The HHI fell 3.7%, to 483.8, underperforming the main London markets – FTSE 100 (+3.8%) and FTSE All-Share (3.8%) but outperforming the FTSE AIM All-Share Index (

PANMURE: Healthcare: Prescribed Reading : 2024 - a year of delivery

PANMURE: Pharma Services : Outsourcing core to pharma; Headwinds easing from YE?

Cambridge Nutritional Sciences - Operational improvements set to drive future gr

Cambridge Nutritional Science’s (CNS) FY 2024 results make for encouraging reading, from both a financial and operational perspective, that should provide investors with confidence around management’s ability to execute on its long-term growth strategy, in our view. Underpinning our positive sentiment is the payback which is now being realised from the group’s manufacturing excellence programmes which have delivered significant growth in the gross margin in FY 2024, increasing 1,488 bps to 61.9%

PANMURE LIBERUM: Inspiration Healthcare: Inspiration catches a break

Morning Note – 25 July 2024

Hybridan Small Cap Feast - 25 July 24

* A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced, or it is a rumour Dish of the day Admissions: None Delistings: None What’s baking in the oven? ** Potential**** Initial Public Offerings: ITF announced: 8th July 2024: Rome Resources: The Canada-based early-stage resource exploration Company has announced its intention to IPO on AIM in order to continue to make

On the mend

Shield Therapeutics - AOP Milestone Monetisation gives comfort on cash position

STX has done a deal with its major shareholder, AOP Health International Management, under which it will get a $5.7m cash advance, to be paid back by the future milestone payment ($11.4m) that STX expects to receive upon the approval of Accrufer in China in 2026. Although the payback terms are favourable to AOP, we would not expect it to further invest if it did not have a clear line of sight to payback via the China approval, and more broadly STX’s ability to become profitable. In today’s relea